This prospective cohort study evaluates ocular outcomes at 12 months’ corrected age in infants whose eyes received a dose of 0.625, 0.25, 0.125, 0.063, or 0.031 mg of bevacizumab for type 1 retinopathy of prematurity.
This cohort study creates and validates an easy-to-use prediction model using only birth characteristics and describes a continuous hazard function for retinopathy of prematurity treatment.
A 55-year-old woman presents with decreased visual acuity, and magnetic resonance imaging shows thickening of the optic nerves and other areas of the brain. Over 5 years, she returns with multiple similar presentations. What would you do next?
This case report describes a 19-month-old boy with a SETD2 mutation in an aggressive optic nerve glioma.
Create a personal account or sign in to: